Portfolio Design Labs LLC Invests $324,000 in Chemed Co. (NYSE:CHE)

Portfolio Design Labs LLC bought a new position in shares of Chemed Co. (NYSE:CHE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 612 shares of the company’s stock, valued at approximately $324,000.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Elevate Capital Advisors LLC purchased a new stake in shares of Chemed during the fourth quarter worth about $1,106,000. Lecap Asset Management Ltd. purchased a new stake in shares of Chemed during the fourth quarter worth about $1,130,000. William Allan Corp increased its stake in shares of Chemed by 13.5% during the fourth quarter. William Allan Corp now owns 8,340 shares of the company’s stock worth $4,418,000 after purchasing an additional 989 shares in the last quarter. Jericho Financial LLP purchased a new stake in shares of Chemed during the fourth quarter worth about $3,142,000. Finally, Boston Trust Walden Corp increased its stake in shares of Chemed by 10.0% during the fourth quarter. Boston Trust Walden Corp now owns 242,172 shares of the company’s stock worth $128,303,000 after purchasing an additional 22,105 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

Wall Street Analysts Forecast Growth

CHE has been the subject of a number of research reports. Royal Bank of Canada cut their target price on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. StockNews.com upgraded shares of Chemed from a “hold” rating to a “buy” rating in a report on Saturday, November 30th.

Chemed Trading Down 0.8 %

CHE stock opened at $549.51 on Thursday. The company has a market cap of $8.27 billion, a price-to-earnings ratio of 27.77, a PEG ratio of 2.16 and a beta of 0.48. Chemed Co. has a 12 month low of $512.12 and a 12 month high of $654.62. The firm has a 50-day moving average of $542.24 and a two-hundred day moving average of $564.74.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $572.77, for a total transaction of $1,145,540.00. Following the completion of the sale, the chief executive officer now owns 101,735 shares in the company, valued at $58,270,755.95. This trade represents a 1.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Spencer S. Lee sold 732 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $575.62, for a total transaction of $421,353.84. Following the sale, the executive vice president now owns 18,287 shares of the company’s stock, valued at $10,526,362.94. This represents a 3.85 % decrease in their position. The disclosure for this sale can be found here. 3.32% of the stock is owned by insiders.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.